Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE004 (DEU) (Dr. Tanaka)
· consented 2023-09-07
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-26 (study day 35); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-19 (study day 59); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-25 (study day 126); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-04-06 (study day 198); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.